UNSPSC 42142627: Insulin syringe

Specialized syringe with markings specific to administration of insulin.

UNSPSC 42142627 Insulin syringe is a Commodity code that covers injectable delivery devices for diabetes management and other medical conditions requiring subcutaneous or intramuscular administration. Recent state and local procurement under this code includes participation in multi-state cooperative pharmaceutical and medical supply contracts rather than insulin-syringe-specific solicitations. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued an RFP in January 2026 to establish multiple contracts for generic pharmaceuticals and OTC products distributed across participating state and local government facilities in Minnesota, Oregon, and other member jurisdictions. Issuing bodies soliciting under this code span state procurement offices, county health systems, and municipal health departments, though recent activity is dominated by cooperative purchasing vehicles that aggregate demand across multiple jurisdictions. The RFP structure emphasizes direct relationships between manufacturers and authorized wholesalers (AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson Co., LLC) with chargeback systems and EDI capability requirements, meaning insulin syringes and similar injectable devices flow through established pharmaceutical supply chains rather than direct government procurement.

Recent activity clusters in states participating in MMCAP, particularly Minnesota and Oregon, though cooperative purchasing agreements typically serve member jurisdictions across multiple regions. The Minnesota Multistate Cooperative Purchasing Alliance RFP (S1070000015802) with a March 26, 2026 response deadline represents the most substantial recent opportunity on this code; it evaluates vendors on price competitiveness (75 percent weight), fixed pricing (10 percent), administrative compliance (5 percent), EDI capability (5 percent), and agreement to a 3 percent administrative fee (5 percent). Vendors must maintain commercial general liability insurance of $5,000,000 per occurrence, network security liability of $2,000,000, and professional liability of $2,000,000, and must certify compliance with current Good Manufacturing Practices and the Drug Supply Chain Security Act. The contract term is two years for new vendors with optional extensions through June 30, 2028 for incumbents, with awarded vendors expected to be provided to wholesalers by May 15, 2026 and the resulting agreements effective July 1, 2026.